Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 81 P140 | DOI: 10.1530/endoabs.81.P140

1Department of Endocrinology, Diabetology, and Metabolism, Lille University Hospital, Lille, France; 2Department of Radiology, Lille University Hospital, Lille, France; 3Department of Ophthalmology, Lille University Hospital, Lille, France; 4Department of Pathology, Lille University Hospital, Lille, France; 5Department of Neurosurgery, Lille University Hospital, Lille, France; 6Department of Biochemistry & Hormonology, Lille University Hospital, Lille, France; 7Department of Endocrinology, Diabetology, and Metabolism, Lille University Hospital, Nord, Lille, France; 8University of Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S1172, Lille, France; 9University of Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S1172, Lille, France


Introduction: Few studies to date have attempted to evaluate the early efficacy of first-generation somatostatin analogs in somatotroph macroadenomas.

Objective: To investigate the short-term efficacy of primary therapy with lanreotide 120 mg on tumor shrinkage and ophthalmologic symptoms in newly diagnosed patients with acromegaly.

Design and patients: This single-center retrospective study included 21 patients who were newly diagnosed with acromegaly resulting from pituitary macroadenoma and were receiving a primary monthly treatment with lanreotide 120 mg. Clinical, hormonal, ophthalmologic and MRI scan evaluations were conducted after the first and the third months of treatment.

Results: Tumor volume reduction was more pronounced at one month [mean volume change -31.4 ± 19.5%, P<0.0001] than between the first and third month of treatment [mean volume reduction -20.6 ± 13.4%, P=0.0009]. The mean volume change between baseline and the third month was -46.4 ± 21.6, (P<0.0001). A significant volume reduction (≥ 25%) was observed in 61.9% of individuals (13/21) at the first month and in 82.3% (14/17) after three months of treatment. Among 14 individuals with optic chiasm compression and visual field defects, visual field normalization was observed in 3 cases (21.4%) and improvement in 7 cases (50%) at one month. The decrease in GH and IGF-1 serum values was significant at one month.

Conclusions: Primary treatment with lanreotide 120 mg in patients with somatotroph macroadenomas provides early significant tumor shrinkage with rapid improvement of visual symptoms at the end of the first month.

Volume 81

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.